Ioannis I. Andreadis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ioannis I. Andreadis has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Christina Karavasili
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
4 shared publications Dimitrios G. Fatouros
Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki GR-54124, Greece
4 shared publications- Dimitrios G. Fatouros
Aristotle University of Thessaloniki
3 shared publications - Georgios K. Eleftheriadis
Laboratory of Pharmaceutical Technology, Department of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
3 shared publications - Christos I. Gioumouxouzis
Laboratory of Pharmaceutical Technology, Department of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications - Dimitrios Tzetzis
Digital Manufacturing and Materials Characterization Laboratory, School of Science and Technology, International Hellenic University, Thessaloniki, Greece
2 shared publications
Latest Publications
- Open Access
- 13 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2782
Correction: Andreadis et al. The Advent of a New Era in Digital Healthcare: A Role for 3D Printing Technologies in Drug Manufacturing? Pharmaceutics 2022, 14, 609
- 13 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2782
Open AccessCorrection: Andreadis et al. The Advent of a New Era in Digital Healthcare: A Role for 3D Printing Technologies in Drug Manufacturing? Pharmaceutics 2022, 14, 609
- Open Access
- 10 March 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 609
The Advent of a New Era in Digital Healthcare: A Role for 3D Printing Technologies in Drug Manufacturing?
The technological revolution has physically affected all manufacturing domains, at the gateway of the fourth industrial revolution. Three-dimensional (3D) printing has already shown its potential in this new reality, exhibiting remarkable applications in the production of drug delivery systems. As part of this concept, personalization of the dosage form by means of individualized drug dose or improved formulation functionalities has concentrated global research efforts. Beyond the manufacturing level, significant parameters must be considered to promote the real-time manufacturing of pharmaceutical products in distributed areas. The majority of current research activities is focused on formulating 3D-printed drug delivery systems while showcasing different scenarios of installing 3D printers in patients’ houses, hospitals, and community pharmacies, as well as in pharmaceutical industries. Such research presents an array of parameters that must be considered to integrate 3D printing in a future healthcare system, with special focus on regulatory issues, drug shortages, quality assurance of the product, and acceptability of these scenarios by healthcare professionals and public parties. The objective of this review is to critically present the spectrum of possible scenarios of 3D printing implementation in future healthcare and to discuss the inevitable issues that must be addressed.
- 10 March 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 609
Open AccessThe Advent of a New Era in Digital Healthcare: A Role for 3D Printing Technologies in Drug Manufacturing?
The technological revolution has physically affected all manufacturing domains, at the gateway of the fourth industrial revolution. Three-dimensional (3D) printing has already shown its potential in this new reality, exhibiting remarkable applications in the production of drug delivery systems. As part of this concept, personalization of the dosage form by means of individualized drug dose or improved formulation functionalities has concentrated global research efforts. Beyond the manufacturing level, significant parameters must be considered to promote the real-time manufacturing of pharmaceutical products in distributed areas. The majority of current research activities is focused on formulating 3D-printed drug delivery systems while showcasing different scenarios of installing 3D printers in patients’ houses, hospitals, and community pharmacies, as well as in pharmaceutical industries. Such research presents an array of parameters that must be considered to integrate 3D printing in a future healthcare system, with special focus on regulatory issues, drug shortages, quality assurance of the product, and acceptability of these scenarios by healthcare professionals and public parties. The objective of this review is to critically present the spectrum of possible scenarios of 3D printing implementation in future healthcare and to discuss the inevitable issues that must be addressed.
- 8 December 2021
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (1) , 274-286
In Situ Gelling Electrospun Ocular Films Sustain the Intraocular Pressure-Lowering Effect of Timolol Maleate: In Vitro, Ex Vivo, and Pharmacodynamic Assessment
Most common intraocular pressure (IOP) reduction regimens for the management of glaucoma include the topical use of eye drops, a dosage form that is associated with short residence time at the site of action, increased dosing frequency, and reduced patient compliance. In situ gelling nanofiber films comprising poly(vinyl alcohol) and Poloxamer 407 were fabricated via electrospinning for the ocular delivery of timolol maleate (TM), aiming to sustain the IOP-lowering effect of the β-blocker, compared to conventional eye drops. The electrospinning process was optimized, and the physicochemical properties of the developed formulations were thoroughly investigated. The fiber diameters of the drug-loaded films ranged between 123 and 145 nm and the drug content between 5.85 and 7.83% w/w. Total in vitro drug release from the ocular films was attained within 15 min following first-order kinetics, showing higher apparent permeability (Papp) values across porcine corneas compared to the drug’s solution. The fabricated films did not induce any ocular irritation as evidenced by both the hen’s egg test on chorioallantoic membrane and the in vivo Draize test. In vivo administration of the ocular films in rabbits induced a faster onset of action and a sustained IOP-lowering effect up to 24 h compared to TM solution, suggesting that the proposed ocular films are promising systems for the sustained topical delivery of TM.
- 8 December 2021
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (1) , 274-286
In Situ Gelling Electrospun Ocular Films Sustain the Intraocular Pressure-Lowering Effect of Timolol Maleate: In Vitro, Ex Vivo, and Pharmacodynamic Assessment
Most common intraocular pressure (IOP) reduction regimens for the management of glaucoma include the topical use of eye drops, a dosage form that is associated with short residence time at the site of action, increased dosing frequency, and reduced patient compliance. In situ gelling nanofiber films comprising poly(vinyl alcohol) and Poloxamer 407 were fabricated via electrospinning for the ocular delivery of timolol maleate (TM), aiming to sustain the IOP-lowering effect of the β-blocker, compared to conventional eye drops. The electrospinning process was optimized, and the physicochemical properties of the developed formulations were thoroughly investigated. The fiber diameters of the drug-loaded films ranged between 123 and 145 nm and the drug content between 5.85 and 7.83% w/w. Total in vitro drug release from the ocular films was attained within 15 min following first-order kinetics, showing higher apparent permeability (Papp) values across porcine corneas compared to the drug’s solution. The fabricated films did not induce any ocular irritation as evidenced by both the hen’s egg test on chorioallantoic membrane and the in vivo Draize test. In vivo administration of the ocular films in rabbits induced a faster onset of action and a sustained IOP-lowering effect up to 24 h compared to TM solution, suggesting that the proposed ocular films are promising systems for the sustained topical delivery of TM.
- 1 November 2020
- Published by Elsevier in Carbohydrate Polymers
- Vol. 247, 116666
Physico-mechanical and finite element analysis evaluation of 3D printable alginate-methylcellulose inks for wound healing applications
- 1 November 2020
- Published by Elsevier in Carbohydrate Polymers
- Vol. 247, 116666
Physico-mechanical and finite element analysis evaluation of 3D printable alginate-methylcellulose inks for wound healing applications
- 28 July 2020
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 21 (6) , 1-10
Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) Containing Rice Bran Oil for Enhanced Fenofibrate Oral Delivery: In Vitro Digestion, Ex Vivo Permeability, and In Vivo Bioavailability Studies
Lipid-based drug delivery systems (LbDDS), such as self-nanoemulsifying drug delivery systems (SNEDDS), constitute a prominent formulation approach for enh
- 28 July 2020
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 21 (6) , 1-10
Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) Containing Rice Bran Oil for Enhanced Fenofibrate Oral Delivery: In Vitro Digestion, Ex Vivo Permeability, and In Vivo Bioavailability Studies
Lipid-based drug delivery systems (LbDDS), such as self-nanoemulsifying drug delivery systems (SNEDDS), constitute a prominent formulation approach for enh
- 1 June 2019
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 51, 177-184
In vitro and ex vivo assessment of microporous Faujasite zeolite (NaX-FAU) as a carrier for the oral delivery of danazol
- 1 June 2019
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 51, 177-184
In vitro and ex vivo assessment of microporous Faujasite zeolite (NaX-FAU) as a carrier for the oral delivery of danazol
- 24 April 2019
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 4 (3) , 139-151
Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics
Introduction: Nowadays, nanotechnology and genomics contribute knowledge and innovative practices, enabling pharmacological interventions as well as theraputic decisions to be applicable on a personal basis, i.e., establishing precision (personalized) medicine approaches into the clinical setting. However, the dynamics and the evolution capacity of organisms over time necessitate the advancement of powerful interdisciplinary tools, population-based pharmacological methodologies, as well as the application of translational methodologies with clinical implementation capabilities. Areas covered: Even for newly emerged techniques, like three-dimensional (3D) bioprinting nanoplatforms and in vitro transcribed (IVT)-mRNA therapeutics, the patients’ heterogeneity still hinders their potential exploitation in a broader perspective and clinical outcome burden. It is thus essential that the recently developed computational physiologically-based pharmacokinetic (PBPK) models present tools aiming to predict differential pharmacological response in patient groups and to allow cost-effective individualized dosage adjustments for populations worldwide. Expert opinion: The recent advancements in IVT-mRNA therapeutics and 3D bioprinting technologies, along with the capabilities of PBPK modeling to delineate the issue of interpatient heterogeneity, will be presented and discussed. Also, the integration of core interdisciplinary infrastructures will be included in a manner to better serve the task of more efficiently and productively achieving precision medicine interventions in the everyday clinical practice.
- 24 April 2019
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 4 (3) , 139-151
Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics
Introduction: Nowadays, nanotechnology and genomics contribute knowledge and innovative practices, enabling pharmacological interventions as well as theraputic decisions to be applicable on a personal basis, i.e., establishing precision (personalized) medicine approaches into the clinical setting. However, the dynamics and the evolution capacity of organisms over time necessitate the advancement of powerful interdisciplinary tools, population-based pharmacological methodologies, as well as the application of translational methodologies with clinical implementation capabilities. Areas covered: Even for newly emerged techniques, like three-dimensional (3D) bioprinting nanoplatforms and in vitro transcribed (IVT)-mRNA therapeutics, the patients’ heterogeneity still hinders their potential exploitation in a broader perspective and clinical outcome burden. It is thus essential that the recently developed computational physiologically-based pharmacokinetic (PBPK) models present tools aiming to predict differential pharmacological response in patient groups and to allow cost-effective individualized dosage adjustments for populations worldwide. Expert opinion: The recent advancements in IVT-mRNA therapeutics and 3D bioprinting technologies, along with the capabilities of PBPK modeling to delineate the issue of interpatient heterogeneity, will be presented and discussed. Also, the integration of core interdisciplinary infrastructures will be included in a manner to better serve the task of more efficiently and productively achieving precision medicine interventions in the everyday clinical practice.